Prognostic value of Alzheimer's disease plasma biomarkers in the oldest-old: a prospective primary care-based study.

ABSTRACT:

Background

Blood-based biomarkers offer a promising, less invasive, and more cost-effective alternative for Alzheimer's disease screening compared to cerebrospinal fluid or imaging biomarkers. However, they have been extensively studied only in memory clinic-based cohorts. We aimed to validate them in a more heterogeneous, older patient population from primary care.

Methods

We measured plasma Aβ42/Aβ40, P-tau181, NfL, and GFAP in 1007 individuals without dementia, aged 79-94 years, from the longitudinal, primary care-based German AgeCoDe study. We assessed the association with cognitive decline, disease progression, and the capacity to predict future dementia of the Alzheimer's type (DAT). We also evaluated biomarker dynamics in 305 individuals with a follow-up sample (∼8 ye

SUBMITTER: Martino-Adami PV 

PROVIDER: S-EPMC11381503 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature